Graphic Evidence: Genetic Technologies Soars on Cancer Test News

Chart: Zignals.com

by Paul Springer 

Australia-based Genetic Technologies Ltd. (GENE) advanced a step closer to marketing a genetic breast cancer test, and investors immediately drove the company’s stock up 85% at midday, when the stock was trading around $5.85. 

At one point it went as high as $6.95. 

While biotech stocks sometimes leap on news of an inscrutably technical nature, the potential value of the company’s BREVAgen test is abundantly clear. 

“The test will help many women by better determining their individual breast cancer risk, and it will help health professionals better determine optimum treatment decisions,” CEO Paul MacLeman said in a news statement

In the U.S. alone, close to 200,000 women are diagnosed with breast cancer every year. The National Breast Cancer Foundation says 40,000 women die from breast cancer every year. 

Analysis of BRCA1 and BRCA2 genes can provide some information on prospects of developing breast cancer, according to the National Cancer Institute. But this testing is only viable with about 10% of the population. 

Genetic Technologies says BREVAgen will provide guidance to the other 90%. 

The company has been developing the test for some time. But markets rose on news that certification of its Australian laboratory has been received under the U.S. Clinical Laboratories Improvements Amendments. 

While the product is not being hailed as a cure for cancer, it could provide crucial information for vast numbers of people – including men – who could be afflicted with breast cancer. 

The company says it expects the test to be available to U.S. doctors and their patients in a few weeks, while distribution in Europe and Asia still awaits regulatory approval.

Related posts:

  1. Market Reacts to Jobs Reportedly Receiving Cancer TreatmentApple co-founder and CEO Steve Jobs has been spotted at the Stanford Cancer Center in Palo Alto, Calif.,...
  2. Graphic Evidence: MELA Rides the AnvilMELA Sciences presented a textbook case of what the FDA can do to a development company’s stock price....
  3. Graphic Evidence: American Apparel Dodges Ch. 11An unexpected dose of cash appears to have provided American Apparel a new lease on life...
  4. Graphic Evidence: Tasty Baking Toasts ShortsTastykakes and Krimpets maker Tasty Baking Co. (TSTY) was up just shy of 30% Friday when its stock...
  5. Graphic Evidence: Sterling Warrants Ride RocketComerica Inc. agreed to buy Sterling Bancshares in an arrangement valuing Sterling at around $10 per share, which...

Short URL: http://www.traderdaily.com/?p=13010

You must be logged in to post a comment Login

Receive TraderDaily by Email

- Yes! Sign me up for TraderDaily by Email
First Name:
Last Name:
Company:
*Email:

Twitter Facebook Linked In RSS Feed

© 2014 TraderDaily. All Rights Reserved.

Videos, Slideshows and Podcasts by Cincopa Wordpress Plugin